| Mrs Suzanne Dawn Phillips, RN, APN, ACNP-BC | |
|
4 Walter E Foran Blvd, Suite 101, Flemington, NJ 08822-4664 | |
| (908) 782-3204 | |
| (908) 788-5279 |
| Full Name | Mrs Suzanne Dawn Phillips |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 4 Walter E Foran Blvd, Flemington, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134376817 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 26NJ00167200 (New Jersey) | Primary |
| Entity Name | Inpatient Consultants Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669422846 PECOS PAC ID: 5991720591 Enrollment ID: O20051012001172 |
News Archive
InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.
If patient engagement is the new 'blockbuster drug,' why are we not seeing spectacular effects? A team of researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Berkeley School of Public Health at UC Berkeley recently conducted a study designed to help answer that question and to better understand how patient engagement and activation practices -like goal-setting, motivational interviewing, and shared decision making-are being integrated into clinical practice.
When this week's print issue of the journal Science comes out, a collective cheer will go up from New Mexico, Montana and even the Netherlands, thanks to the type of collaborative effort that is more and more the norm in these connected times. Yes, the research was brilliant, and if we're lucky, it will produce innovations in biology, medicine, biotechnology and agriculture. It could save lives, and it happened because this scientist talked with that one, that one knew another one, and brilliant minds overcame geographic distance to advance human understanding.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.
› Verified 5 days ago
| Entity Name | Nm Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366928749 PECOS PAC ID: 3375892060 Enrollment ID: O20200109003016 |
News Archive
InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.
If patient engagement is the new 'blockbuster drug,' why are we not seeing spectacular effects? A team of researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Berkeley School of Public Health at UC Berkeley recently conducted a study designed to help answer that question and to better understand how patient engagement and activation practices -like goal-setting, motivational interviewing, and shared decision making-are being integrated into clinical practice.
When this week's print issue of the journal Science comes out, a collective cheer will go up from New Mexico, Montana and even the Netherlands, thanks to the type of collaborative effort that is more and more the norm in these connected times. Yes, the research was brilliant, and if we're lucky, it will produce innovations in biology, medicine, biotechnology and agriculture. It could save lives, and it happened because this scientist talked with that one, that one knew another one, and brilliant minds overcame geographic distance to advance human understanding.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Suzanne Dawn Phillips, RN, APN, ACNP-BC 4 Walter E Foran Blvd, Suite 101, Flemington, NJ 08822-4664 Ph: (908) 782-3204 | Mrs Suzanne Dawn Phillips, RN, APN, ACNP-BC 4 Walter E Foran Blvd, Suite 101, Flemington, NJ 08822-4664 Ph: (908) 782-3204 |
News Archive
InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.
If patient engagement is the new 'blockbuster drug,' why are we not seeing spectacular effects? A team of researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Berkeley School of Public Health at UC Berkeley recently conducted a study designed to help answer that question and to better understand how patient engagement and activation practices -like goal-setting, motivational interviewing, and shared decision making-are being integrated into clinical practice.
When this week's print issue of the journal Science comes out, a collective cheer will go up from New Mexico, Montana and even the Netherlands, thanks to the type of collaborative effort that is more and more the norm in these connected times. Yes, the research was brilliant, and if we're lucky, it will produce innovations in biology, medicine, biotechnology and agriculture. It could save lives, and it happened because this scientist talked with that one, that one knew another one, and brilliant minds overcame geographic distance to advance human understanding.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.
› Verified 5 days ago
Elizabeth Philip, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1100 Wescott Dr Ste G3, Flemington, NJ 08822 Phone: 908-788-1710 Fax: 908-806-2050 | |
Elizabeth Mcgourty, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 State Route 31 Ste 111, Flemington, NJ 08822 Phone: 908-284-9880 Fax: 908-782-4316 | |
Dianne C Lakata, RN.,APNC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2100 Wescott Dr, Hbh, Flemington, NJ 08822 Phone: 908-788-6401 Fax: 908-788-6584 | |
Ms. Linda Marie Schnupp, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 9100 Westcott Dr, Suite 103, Flemington, NJ 08822 Phone: 908-788-8200 | |
Mrs. Kathryn A. Wall, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 190 Rt. 31, Ste. 100, Flemington, NJ 08822 Phone: 908-788-6654 Fax: 908-788-6452 | |
Carol Smigelsky, N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 111 State Route 31, Suite 121, Flemington, NJ 08822 Phone: 908-782-2825 Fax: 908-782-0196 | |
Kirsten S Posselt, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2100 Wescott Dr, Flemington, NJ 08822 Phone: 908-237-5420 |